Abstract
Several genomic epidemiology tools have been developed to track the public and population health impact of SARS-CoV-2 community spread worldwide. A SARS-CoV-2 Variant of Concern (VOC) B.1.1.7, known as 501Y.V1, which shows increased transmissibility, has rapidly become the dominant VOC in the United States (US). Our objective was to develop an evidenced-based genomic surveillance algorithm that combines RT-PCR and sequencing technologies to identify VOCs. Deidentified data were obtained from 508,969 patients tested for COVID-19 with the TaqPath COVID-19 RT-PCR Combo Kit (ThermoFisher) in four CLIA certified clinical laboratories in Puerto Rico (n=86,639) and in three CLIA certified clinical laboratories in the US (n=422,330). TaqPath data revealed a frequency of S Gene Target Failure (SGTF) >47% for the last week of March 2021, in both Puerto Rico and US laboratories. The monthly frequency of SGTF in Puerto Rico steadily increased exponentially from 4% in November 2020 to 47% in March 2021.The weekly SGTF rate in US samples was high (>8%) from late December to early January, and then also increased exponentially through April (48%). The exponential increase in SGFT prevalence in Puerto Rico is concurrent with a sharp increase in VOCs among all SARS-CoV-2 sequences from Puerto Rico uploaded to GISAID (n=461). B.1.1.7 frequency increased from <1% in the last week of January 2021 to 51.5% of viral sequences from Puerto Rico collected in the last week of March 2021. The exponential increase in SGTF and B.1.1.7 prevalence in Puerto Rico and US requires an urgent response. According to the proposed evidence-based algorithm, approximately 50% of all positive samples should be managed as potential B.1.1.7 carriers with VOC quarantine and contact tracing protocols while their lineage is confirmed by WGS in surveillance laboratories. Patients infected with VOCs should be effectively triaged for isolation, contact tracing and follow-up treatment purposes.
Competing Interest Statement
M.J.M., R.B., N.B., G.K., J.M., C.E.M., and U.P., work for Tempus Labs. R.G.P. works for LifeGene-Biomarks. All other authors declare no competing interests.
Funding Statement
This research was supported by: National Institute on Minority Health and Health Disparities Small Business Innovation Research Fast Track Phase 1 / Phase 2 award (R44MD014911) and Fideicomiso de Ciencia y Tecnologia de Puerto Rico Small Business Innovation Research Phase 1 Cash Match Award (R. Guerrero-Preston); MD007579: Research Centers in Minority Institutions Center for Research Resources, and Puerto Rico Science and Technology Research Trust (V. Rivera-Amill) under agreement 2020-00259; and National Cancer Institute U01CA84986 (D. Sidransky).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University of Puerto Rico Medical Sciences Campus (MSC) IRB approval # IRB2770120.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Materials availability Data availability Genomic data are available on GISAID (see Supplemental S3 for accession numbers). Supplemental Information Description Supplemental S1. Supplemental Methods, Supplemental Resutls, Supplemental Tables, Supplemental Notes. Supplemental S2. Data for Figures 2-4. Supplemental S3. List of SARS-CoV-2 sequences used in this study and author acknowledgements.